Table 3 Cost* and other data summarized
From: An economic model of long-term use of celecoxib in patients with osteoarthritis
| Â | Base case (range) | Reference |
|---|---|---|
Celecoxib 200 mg/d | $2.64 ($2.11–$3.17) | |
Naproxen 1000 mg/d | $0.45 ($0.36–$0.54) | |
Diclofenac 100 mg/d | $0.64 ($0.51–$0.77) | |
Omeprazole (over-the-counter) 20 mg/d | $0.60 ($0.48–$0.72) | |
Price reduction generic celecoxib | 55% (30%–80%) | [61,63] |
POB inpatient-hospital plus physician (ALOS = 5.56 days) | $12,796 ($10,234–$15,355) | [12,40] |
POB outpatient-hospital plus physician | $1,813 ($1,450–$2,176) | [12,160,161] |
Peptic ulcer inpatient-hospital plus physician (ALOS = 4.10 days) | $7,353 ($5,882–$8,824) | [12,40] |
Peptic ulcer outpatient discrete event including endoscopy | $1,554 ($1,243–$1,865) | [12,160,161] |
Dyspepsia outpatient initial event including endoscopy | $1,208 ($966–$1,450) | [12,160,161] |
Ongoing annual medical and laboratory costs chronic peptic ulcer or dyspepsia | $130 ($104–$156) | [160], Estimates RBRVS |
POB proportion of surgery DRGs | 14.2% | [40] |
POB admissions through emergency | 89.7% | [40] |
Proportion of peptic ulcer patients admitted to hospital | 4.37% | [40] |
Discount rate for costs and QALYs | 3.0% | Â |
Price inflation rate | 2.0% | Â |